路易氏体失智症治疗药物市场：按药物类型、分销管道、应用分类 - 全球预测 2025-2030

路易氏体失智症药物市场2023年估值为61.2亿美元，预计到2024年将达到66亿美元，复合年增长率为8.54%，到2030年将达到108.7亿美元。

路易氏体失智症(LBD) 的治疗包括多种治疗策略来控制这种进行性脑部疾病的症状，其特征是会出现影响认知表现、运动和情绪的异常蛋白质沉积。随着人口老化，对有效 LBD 治疗的需求不断增加，需要乙酰胆碱酯酶抑制剂和抗精神病药物等针对性的方法。这些治疗方法主要应用于医疗机构，例如医院和专门的失智症护理机构，以满足 LBD 患者的神经和精神需求。从市场角度来看，医疗保健专业人员和看护者对 LBD 的认识不断提高，推动了对更有效、更全面的治疗方案的需求。关键的成长要素包括神经退化性疾病研究的进展、药物研发投资的增加以及政府对失智症护理倡议的津贴增加。潜在的商机在于开发副作用较少的新药、根据个人基因特征量身定制的个人化医疗方法，以及用于症状管理的穿戴式装置等技术创新。然而，市场开拓面临药物开发成本高、监管障碍高、LBD诊断复杂等限制，常导致误诊和延误治疗。公司可以透过专注于将人工智慧融入早期诊断、增强病患监测系统以及探索联合治疗的潜力来进行创新。提供远距离诊断和远端系统管理的远端医疗解决方案的潜力也越来越大，可以显着提高患者和看护者的参与度。随着市场的发展，由于提供创新解决方案的新进入者的涌入，竞争可能会加剧。儘管有这些挑战，公司可以透过策略联盟获得竞争优势，专注于未满足的临床需求，并保持敏捷的研发方法，以帮助管理 LBD 带来重大突破。

市场动态：快速发展的路易氏体失智症治疗市场的关键市场洞察

路易氏体失智症治疗市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

• 市场驱动因素
  • 路易氏体失智症盛行率增加且缺乏相关药物
  • 政府努力提高人们对路易氏体失智症的意识提升
  • 路易氏体失智症治疗药物优惠报销规定
• 市场限制因素
  • 与长期照护需求相关的高治疗费用
• 市场机会
  • 路易氏体失智症治疗的临床试验迅速增加
  • 各国医疗保健设施的增加
• 市场挑战
  • 药物可能产生的副作用

波特的五力：驾驭路易氏体失智症药物市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对路易氏体失智症治疗药物市场的影响

外部宏观环境因素在塑造路易氏体失智症治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解路易氏体失智症治疗药物市场的竞争状况

对路易氏体失智症治疗药物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 路易氏体失智症治疗药物市场中的定位矩阵供应商绩效评估

FPNV 定位矩阵是评估路易氏体失智症治疗药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘路易氏体失智症治疗药物市场的成功之路

对路易氏体失智症治疗药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

• 市场动态
  • 促进因素
    • 缺乏与路易氏体失智症盛行率增加相关的药物
    • 政府努力提高人们对路易氏体失智症的认识
    • 路易氏体失智症治疗的有利报销规则
  • 抑制因素
    • 治疗费用高，需长期护理
  • 机会
    • 路易氏体失智症治疗药物的临床试验数量正在迅速增加
    • 各国医疗保健设施的增加
  • 任务
    • 药物可能产生的副作用
• 市场区隔分析
• 波特五力分析
• PESTEL分析
  • 政治的
  • 经济
  • 社群
  • 技术的
  • 合法地
  • 环境

第六章依药物类型分類的路易氏体失智症治疗市场

• 抗忧郁症
• 抗精神病药
• 苯二氮平类
• Carbidopa-Levodopa
• 胆碱酯酶抑制剂
  • 多奈哌齐
  • Galantamine
  • Rivastigmine
• Modafinil

第七章路易氏体失智症治疗药物市场：按分销管道

• 网路药房
• 零售药房

第八章路易氏体失智症治疗药物市场：依应用分类

• 阿兹海默症
• 失智
• 帕金森氏症

第九章北美和南美路易氏体失智症治疗市场

• 阿根廷
• 巴西
• 加拿大
• 墨西哥
• 美国

第十章亚太地区路易氏体失智症治疗药物市场

• 澳洲
• 中国
• 印度
• 印尼
• 日本
• 马来西亚
• 菲律宾
• 新加坡
• 韩国
• 台湾
• 泰国
• 越南

第十一章欧洲、中东和非洲路易氏体失智症治疗药物市场

• 丹麦
• 埃及
• 芬兰
• 法国
• 德国
• 以色列
• 义大利
• 荷兰
• 奈及利亚
• 挪威
• 波兰
• 卡达
• 俄罗斯
• 沙乌地阿拉伯
• 南非
• 西班牙
• 瑞典
• 瑞士
• 土耳其
• 阿拉伯聯合大公国
• 英国

第十二章竞争格局

• 2023 年市场占有率分析
• FPNV 定位矩阵，2023
• 竞争情境分析
• 战略分析和建议

公司名单

• Axovant Sciences Ltd.
• Bausch Health Companies Inc.
• Bayer AG
• BioArctic AB
• Eisai Co., Ltd.
• Eli Lilly and Company
• Immungenetics AG
• Jazz Pharmaceuticals, Inc
• Mallinckrodt Pharmaceuticals
• Novartis AG
• Noven Pharmaceuticals, Inc
• Pfizer Inc
• Sumitomo Dainippon Pharma Co., Ltd
• Takeda Pharmaceutical Company Ltd.

The Lewy Body Dementia Treatment Market was valued at USD 6.12 billion in 2023, expected to reach USD 6.60 billion in 2024, and is projected to grow at a CAGR of 8.54%, to USD 10.87 billion by 2030.

Lewy Body Dementia (LBD) treatment encompasses various therapeutic strategies to manage symptoms of this progressive brain disorder, characterized by abnormal protein deposits affecting cognitive abilities, movement, and mood. The necessity for effective LBD treatments is growing as the aging population increases, necessitating targeted approaches like acetylcholinesterase inhibitors and antipsychotics. These treatments are primarily applied in healthcare settings, including hospitals and specialized dementia care facilities, catering to LBD patients' neurological and psychiatric needs. From a market perspective, the growing awareness of LBD among healthcare professionals and caregivers drives demand for more effective and inclusive therapeutic options. Key growth factors include advances in neurodegenerative disease research, heightened investment in pharmaceutical R&D, and increasing government funding in dementia care initiatives. Potential opportunities lie in developing novel drugs with fewer side effects, personalized medicine approaches tailored to individual genetic profiles, and technological innovations like wearable devices for symptom management. However, the market faces limitations such as the high cost of drug development, significant regulatory hurdles, and the complexity of diagnosing LBD, often leading to misdiagnosis or delayed treatment. Companies can innovate by focusing on integrating artificial intelligence in early diagnosis, enhancing patient monitoring systems, and exploring the potential of combination therapies. There's also a growing scope for telemedicine solutions providing remote diagnosis and management, which can significantly enhance patient and caregiver engagement. As the market evolves, the competition may intensify with an influx of new entrants offering innovative solutions. Despite these challenges, businesses can gain competitive advantages through strategic collaborations, focusing on unmet clinical needs, and maintaining an agile approach to research and development, which can lead to significant breakthroughs in managing LBD.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Lewy Body Dementia Treatment Market

The Lewy Body Dementia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of lewy body dementia and absence of concerned drug
  • Government initiatives for creating awareness about lewy body dementia
  • Favorable reimbursement regulations pertaining to lewy body dementia treatment
• Market Restraints
  • High treatment cost along with need of long term care
• Market Opportunities
  • Burgeoning number of performed clinical trials for lewy body dementia treatment
  • Growing healthcare facilities in countries
• Market Challenges
  • Possible adverse effects of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Lewy Body Dementia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Lewy Body Dementia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Lewy Body Dementia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Lewy Body Dementia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Lewy Body Dementia Treatment Market

A detailed market share analysis in the Lewy Body Dementia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Lewy Body Dementia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Lewy Body Dementia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Lewy Body Dementia Treatment Market

A strategic analysis of the Lewy Body Dementia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Lewy Body Dementia Treatment Market, highlighting leading vendors and their innovative profiles. These include Axovant Sciences Ltd., Bausch Health Companies Inc., Bayer AG, BioArctic AB, Eisai Co., Ltd., Eli Lilly and Company, Immungenetics AG, Jazz Pharmaceuticals, Inc, Mallinckrodt Pharmaceuticals, Novartis AG, Noven Pharmaceuticals, Inc, Pfizer Inc, Sumitomo Dainippon Pharma Co., Ltd, and Takeda Pharmaceutical Company Ltd..

Market Segmentation & Coverage

This research report categorizes the Lewy Body Dementia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Type, market is studied across Antidepressants, Antipsychotic Drugs, Benzodiazepine, Carbidopa-Levodopa, Cholinesterase Inhibitors, and Modafinil. The Cholinesterase Inhibitors is further studied across Donepezil, Galantamine, and Rivastigmine.
• Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies.
• Based on Application, market is studied across Alzheimer's Disease, Dementia, and Parkinson's Disease.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of lewy body dementia and absence of concerned drug
    • 5.1.1.2. Government initiatives for creating awareness about lewy body dementia
    • 5.1.1.3. Favorable reimbursement regulations pertaining to lewy body dementia treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High treatment cost along with need of long term care
  • 5.1.3. Opportunities
    • 5.1.3.1. Burgeoning number of performed clinical trials for lewy body dementia treatment
    • 5.1.3.2. Growing healthcare facilities in countries
  • 5.1.4. Challenges
    • 5.1.4.1. Possible adverse effects of drugs
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Lewy Body Dementia Treatment Market, by Drug Type

• 6.1. Introduction
• 6.2. Antidepressants
• 6.3. Antipsychotic Drugs
• 6.4. Benzodiazepine
• 6.5. Carbidopa-Levodopa
• 6.6. Cholinesterase Inhibitors
  • 6.6.1. Donepezil
  • 6.6.2. Galantamine
  • 6.6.3. Rivastigmine
• 6.7. Modafinil

7. Lewy Body Dementia Treatment Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Online Pharmacies
• 7.3. Retail Pharmacies

8. Lewy Body Dementia Treatment Market, by Application

• 8.1. Introduction
• 8.2. Alzheimer's Disease
• 8.3. Dementia
• 8.4. Parkinson's Disease

9. Americas Lewy Body Dementia Treatment Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Lewy Body Dementia Treatment Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Lewy Body Dementia Treatment Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Axovant Sciences Ltd.
• 2. Bausch Health Companies Inc.
• 3. Bayer AG
• 4. BioArctic AB
• 5. Eisai Co., Ltd.
• 6. Eli Lilly and Company
• 7. Immungenetics AG
• 8. Jazz Pharmaceuticals, Inc
• 9. Mallinckrodt Pharmaceuticals
• 10. Novartis AG
• 11. Noven Pharmaceuticals, Inc
• 12. Pfizer Inc
• 13. Sumitomo Dainippon Pharma Co., Ltd
• 14. Takeda Pharmaceutical Company Ltd.

LIST OF FIGURES

• FIGURE 1. LEWY BODY DEMENTIA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. LEWY BODY DEMENTIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. LEWY BODY DEMENTIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. LEWY BODY DEMENTIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. LEWY BODY DEMENTIA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ANTIPSYCHOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY BENZODIAZEPINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CARBIDOPA-LEVODOPA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY MODAFINIL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DEMENTIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 38. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 40. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. CANADA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 44. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 45. MEXICO LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. UNITED STATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 55. ASIA-PACIFIC LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 58. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. AUSTRALIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 62. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. CHINA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 66. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. INDIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 70. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. INDONESIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 74. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. JAPAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 78. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. MALAYSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 82. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. PHILIPPINES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 86. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SINGAPORE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 90. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SOUTH KOREA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 94. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. TAIWAN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 98. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. THAILAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 102. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 103. VIETNAM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. EUROPE, MIDDLE EAST & AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 111. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 112. DENMARK LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 115. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. EGYPT LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 119. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. FINLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 123. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 124. FRANCE LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 127. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. GERMANY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 131. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. ISRAEL LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 135. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 136. ITALY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 139. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. NETHERLANDS LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 143. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. NIGERIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 147. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 148. NORWAY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 151. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. POLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 153. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 155. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 156. QATAR LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 159. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 160. RUSSIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 163. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 164. SAUDI ARABIA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH AFRICA LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 171. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 172. SPAIN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 175. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 176. SWEDEN LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 179. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 180. SWITZERLAND LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 183. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 184. TURKEY LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 187. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 188. UNITED ARAB EMIRATES LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2030 (USD MILLION)
• TABLE 191. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 192. UNITED KINGDOM LEWY BODY DEMENTIA TREATMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. LEWY BODY DEMENTIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 194. LEWY BODY DEMENTIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023